In WALTHAM, Massachusetts, on April 03, 2026, Xilio Therapeutics, Inc. revealed that it granted non-qualified stock options to two new employees on April 1, 2026. The options enable the purchase of 3,257 shares of the company's common stock under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan. Xilio Therapeutics is a clinical-stage biotechnology firm focusing on developing masked immuno-oncology therapies for individuals battling cancer. The company trades on Nasdaq under the ticker symbol XLO.